Generic Ozempic Injection ( Semaglutide )

Buy Generic Ozempic Injection (Semaglutide) without prescription in Canada

In our Canadian pharmacy, you can buy Ozempic (Semaglutide) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Ozempic (semaglutide) is a once‑weekly injectable glucagon‑like peptide‑1 (GLP‑1) receptor agonist used for the treatment of type 2 diabetes mellitus in adults, and it is also prescribed off‑label for chronic weight management in Canada. It works by mimicking the action of the body’s own GLP‑1 hormone, which stimulates insulin secretion from the pancreas in a glucose‑dependent manner, suppresses glucagon release, and slows gastric emptying. These combined effects help to lower blood sugar levels, reduce appetite, and promote weight loss, making it a versatile tool in comprehensive diabetes and weight‑management plans.

Usual adult dose: Ozempic is available as a solution for subcutaneous injection in pre‑filled pens. The recommended starting dose is 0.25 mg injected once weekly for 4 weeks; this dose is not effective for glycemic control and is intended only for treatment initiation. After 4 weeks, the dose is increased to 0.5 mg once weekly. For patients who require additional glycemic control, the dose may be further increased to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. The 2.0 mg once‑weekly dose is also available in Canada for patients needing additional blood sugar control. The maximum dose in Canada is 2 mg once weekly. Importantly, the 5 mg dosing schedule refers to the total amount of semaglutide contained within a pre‑filled pen (a 2 mg/1.5 mL pen contains 3 mg total; a 4 mg/3 mL pen contains 4 mg total), not a single 5 mg injection. The medication is injected subcutaneously into the abdomen, thigh, or upper arm, on the same day each week, at any time of day, with or without meals.

Dosage form: Solution for subcutaneous injection in a pre‑filled, multi‑dose disposable pen. Each pen contains either 2 mg/1.5 mL (1.34 mg/mL) or 4 mg/3 mL (1.34 mg/mL) of semaglutide. The 5 mg total pen strength refers to a 4 mg/3 mL pen designed to deliver doses of 0.25 mg, 0.5 mg, and 1 mg. A separate 2 mg/1.5 mL pen delivers the 2 mg dose.

Onset of action: Clinically meaningful reductions in fasting plasma glucose are observed within the first week of treatment, with near‑maximal reductions in HbA1c typically achieved after 12 to 16 weeks of continuous therapy. Weight loss occurs gradually over several months.

Duration of action: The elimination half‑life of semaglutide is approximately 1 week, allowing for once‑weekly dosing. Steady‑state plasma concentrations are reached after 4 to 5 weeks of regular weekly administration.

Alcohol recommendation: Alcohol consumption should be limited or avoided during treatment with Ozempic. Alcohol can cause hypoglycaemia (low blood sugar) when consumed on an empty stomach, and it may worsen the gastrointestinal side effects of semaglutide, such as nausea and vomiting. Patients should discuss safe alcohol intake with their healthcare provider.

Most common side effects: Nausea, vomiting, diarrhoea, abdominal pain, and constipation. These gastrointestinal effects are most common when starting therapy or after dose increases and typically diminish over time. Other common side effects include decreased appetite, dyspepsia, and fatigue. Rare but serious side effects include pancreatitis, gallbladder disease, acute kidney injury, and medullary thyroid carcinoma (boxed warning).

Would you like to try Ozempic (Semaglutide) without a prescription?

General Information about Ozempic (Semaglutide)

• INN (International Nonproprietary Name): Semaglutide
• Brand names available in Canada: Ozempic® (Novo Nordisk Canada Inc.) is the brand‑name product. As of April 28‑May 1, 2026, Health Canada authorized the first two generic semaglutide injections: one from Dr. Reddy’s Laboratories and another from Apotex Inc. (marketed under the brand names Plosbrio™ and Poviztra™). These generics are approved for the same indications as the reference biologic drug Ozempic.
• ATC code: A10BJ06 (blood glucose lowering drugs, excl. insulins: glucagon‑like peptide‑1 receptor agonists).
• Dosage forms and strengths: Pre‑filled, disposable, multi‑dose pens: 2 mg/1.5 mL (1.34 mg/mL) delivering doses of 0.25 mg and 0.5 mg; 4 mg/3 mL (1.34 mg/mL) delivering doses of 1 mg; and a separate 2 mg/1.5 mL pen for the 2 mg dose. Each pen contains multiple doses.
• Manufacturers in Canada: Novo Nordisk Canada Inc. (Ozempic), Dr. Reddy’s Laboratories Ltd. (first generic), Apotex Inc. (second generic).
• Registration status in Canada: Approved by Health Canada. The original brand Ozempic received its Notice of Compliance on January 4, 2018. Generic versions were authorized in April/May 2026. DINs: 02471469 (Ozempic 1 mg pen), 02540258 (Ozempic 0.25/0.5 mg pen).
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. Semaglutide is not available over the counter and requires a valid prescription from a licensed Canadian healthcare professional.

Mechanism of Action and Pharmacology

Semaglutide is a modified human glucagon‑like peptide‑1 (GLP‑1) receptor agonist with 94% sequence homology to native human GLP‑1. It binds to and activates GLP‑1 receptors, which are widely distributed in the pancreas, gastrointestinal tract, brain, heart, kidneys, and liver. Its primary mechanism of action in lowering blood glucose involves glucose‑dependent stimulation of insulin secretion from pancreatic beta‑cells and suppression of glucagon secretion from alpha‑cells. These effects occur only when blood glucose levels are elevated, thereby reducing the risk of hypoglycaemia. Additionally, semaglutide induces a minor delay in gastric emptying during the early postprandial phase, which blunts the rise in blood glucose after meals. In the brain, semaglutide acts on GLP‑1 receptors in the hypothalamus and brainstem to reduce appetite and promote satiety, leading to weight loss. Semaglutide is structurally modified with a C‑18 fatty diacid chain that enables reversible binding to albumin, prolonging its half‑life to approximately one week and allowing once‑weekly subcutaneous administration. Peak plasma concentrations are reached 1 to 3 days after injection, and steady‑state exposure is achieved after 4 to 5 weeks of once‑weekly dosing. The drug is metabolized by proteolytic cleavage of the peptide backbone and by beta‑oxidation of the fatty acid side chain, with excretion primarily in the urine and faeces.

Indications

• Type 2 Diabetes Mellitus: Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It may be used as monotherapy or in combination with other glucose‑lowering agents, including metformin, sulfonylureas, sodium‑glucose cotransporter 2 (SGLT2) inhibitors, or basal insulin. A cardiovascular outcomes trial (SUSTAIN‑6) demonstrated that Ozempic reduced the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease.
• Chronic Weight Management (Off‑label in Canada): Semaglutide 2.4 mg (Wegovy®) is approved in Canada for chronic weight management in adults with obesity or overweight with at least one weight‑related comorbidity. While the 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses of Ozempic are not formally approved for weight loss, they are widely prescribed off‑label for this purpose. As of April 2026, Health Canada has not authorized generic semaglutide for the chronic weight management indication.
• Ozempic is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
• Not recommended for use in children and adolescents under 18 years of age; safety and efficacy have not been established in this population.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Ozempic should not be used during pregnancy. Animal studies have shown reproductive toxicity. It is recommended that Ozempic be discontinued at least 2 months before a planned pregnancy to allow for washout of the drug. Women of childbearing potential should use effective contraception during treatment.
• Breastfeeding: It is not known whether semaglutide is excreted in human breast milk. A risk to the nursing infant cannot be excluded. Ozempic is not recommended during breastfeeding.
• Paediatrics (< 18 years): Safety and efficacy have not been established. Ozempic is not indicated for use in children and adolescents.
• Elderly: No dose adjustment is required based on age. However, therapeutic experience in patients ≥ 75 years is limited, and these patients may be more susceptible to the gastrointestinal side effects and volume depletion that can lead to acute kidney injury.
• Renal impairment: No dose adjustment is required for patients with mild, moderate, or severe renal impairment, including those with end‑stage renal disease on dialysis. However, semaglutide can cause nausea, vomiting, and diarrhoea leading to volume depletion, which may worsen renal function. Renal function should be monitored when initiating or escalating the dose in patients with pre‑existing kidney disease.
• Hepatic impairment: No dose adjustment is required in patients with mild to moderate hepatic impairment. Ozempic has not been studied in patients with severe hepatic impairment and should be used with caution.
• Medullary Thyroid Carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): Ozempic carries a boxed warning for the risk of thyroid C‑cell tumours, including medullary thyroid carcinoma, based on animal studies. It is contraindicated in patients with a personal or family history of MTC or MEN 2. Patients should be counselled regarding the risk of MTC and the symptoms of thyroid tumours (a mass in the neck, dysphagia, dyspnoea, persistent hoarseness).
• Pancreatitis: Acute pancreatitis, including fatal and non‑fatal haemorrhagic or necrotizing pancreatitis, has been reported in patients taking GLP‑1 receptor agonists. Ozempic should be discontinued immediately if pancreatitis is suspected, and it should not be restarted if pancreatitis is confirmed. Patients should be informed of the characteristic symptoms of acute pancreatitis: persistent severe abdominal pain that may radiate to the back.
• Gallbladder disease: GLP‑1 receptor agonists, including semaglutide, have been associated with an increased risk of cholelithiasis and cholecystitis. A Canadian class‑action lawsuit has been filed alleging that the manufacturers failed to adequately warn of these risks. Patients should be monitored for signs of gallbladder disease, and Ozempic should be discontinued if cholecystitis is suspected.
• Diabetic retinopathy: Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression.
• Hypoglycaemia: When Ozempic is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin, the risk of hypoglycaemia is increased. A reduction in the dose of the secretagogue or insulin may be necessary.
• Gastrointestinal adverse reactions: Severe gastrointestinal adverse reactions, including gastroparesis (stomach paralysis) and intestinal obstruction, have been reported with semaglutide. These events may occur at any time during treatment and have been reported in patients without pre‑existing gastrointestinal disease. Health Canada has logged nearly 12,000 adverse reaction reports linked to semaglutide‑containing products since their introduction to the Canadian market.
• Allergy: Do not use Ozempic if you have a known hypersensitivity to semaglutide or any excipient in the formulation.

Driving and alcohol

Ozempic is not expected to impair the ability to drive or operate machinery directly. However, patients should be cautioned about the risk of hypoglycaemia when Ozempic is used in combination with a sulfonylurea or insulin. Signs and symptoms of hypoglycaemia (e.g., dizziness, confusion, blurred vision) may impair the ability to drive. Alcohol consumption should be limited or avoided during treatment. Alcohol can cause hypoglycaemia, especially when taken on an empty stomach, and it may increase the risk of gastrointestinal side effects such as nausea and vomiting. Patients should be counselled to monitor their blood glucose and to avoid driving if hypoglycaemic symptoms occur.

Dosage Instructions

• Initiation and titration: The recommended starting dose is 0.25 mg subcutaneously once weekly for 4 weeks. This dose is intended only for treatment initiation and is not effective for glycemic control. After 4 weeks, increase to 0.5 mg once weekly. For additional glycemic control, the dose may be increased to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. The 2 mg dose is available for patients who require further blood sugar lowering.
• Missed dose: If a dose is missed, administer Ozempic as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can resume their regular once‑weekly dosing schedule.
• Day of weekly administration: The weekly dosing day may be changed if necessary, as long as the time between two doses is at least 3 days (more than 72 hours).
• Administration: Ozempic is injected subcutaneously into the abdomen, thigh, or upper arm. The injection site can be rotated without dose adjustment. Inspect the pen before use; the solution should be clear and colourless. Do not use if the solution is cloudy, discoloured, or contains particulate matter. Do not inject into areas of lipodystrophy, scarred, or bruised skin. Ozempic can be administered at any time of day, with or without meals.
• Switching from another GLP‑1 receptor agonist: When switching from another GLP‑1 receptor agonist to Ozempic, the 0.25 mg initiation dose should be used for 4 weeks before escalating to 0.5 mg, regardless of the dose of the previous agent.
• Concomitant use with insulin: Ozempic and insulin should be administered as two separate injections. The two products may be injected into the same body region, but the injections should not be adjacent to each other.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Nausea (15‑20%), diarrhoea (8‑17%), and vomiting (5‑11%). These gastrointestinal side effects are most common during the first few weeks of therapy and after dose increases; they are usually mild to moderate in severity and diminish over time.
• Common side effects (1‑10%): Abdominal pain, abdominal distension, constipation, dyspepsia, decreased appetite, fatigue, dizziness, and injection‑site reactions (erythema, pruritus, rash).
• Less common but serious side effects: Acute pancreatitis (including necrotizing and haemorrhagic pancreatitis, fatal in rare cases), acute cholecystitis and cholelithiasis, acute kidney injury (particularly in the setting of volume depletion from gastrointestinal losses), diabetic retinopathy complications, gastroparesis, ileus, and intestinal obstruction. Hypoglycaemia occurs primarily when Ozempic is combined with a sulfonylurea or insulin.
• Rare but serious adverse reactions: Medullary thyroid carcinoma (including cases reported in post‑marketing surveillance), anaphylaxis, angioedema, and hypersensitivity reactions. Heart rate increase of 2 to 3 beats per minute from baseline has been observed in clinical trials.
• Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or any of the excipients. Pregnancy and breastfeeding.

Drug Interactions

• Oral medications: Semaglutide delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology studies, semaglutide did not produce clinically relevant changes in the absorption of metformin, atorvastatin, digoxin, warfarin, or an oral contraceptive combination (ethinyl estradiol/levonorgestrel). However, caution should be exercised when co‑administering oral medications with a narrow therapeutic index or those that require rapid gastrointestinal absorption.
• Insulin and insulin secretagogues (e.g., sulfonylureas): The risk of hypoglycaemia is increased. A reduction in the dose of the insulin secretagogue or insulin may be required.
• Warfarin and other coumarin derivatives: Monitor the international normalized ratio (INR) more frequently when initiating or discontinuing Ozempic in patients on warfarin.
• Drugs that affect gastric pH: No clinically relevant effect of elevated gastric pH on the pharmacokinetics of semaglutide has been observed.
• Alcohol and food: Alcohol may increase the risk of hypoglycaemia when consumed on an empty stomach and may exacerbate gastrointestinal side effects. Patients should be counselled to eat regular meals and to limit alcohol intake.

Practical Advice

• Administration: Ozempic is administered once weekly, on the same day each week, at any time of day, with or without meals. Before first use, your healthcare provider will show you how to properly inject Ozempic. Inspect the pen: the solution should be clear and colourless. Attach a new needle before each injection. Prime the pen before the first use of each new pen. Inject into the abdomen, thigh, or upper arm. Rotate injection sites with each dose to reduce the risk of lipodystrophy.
• Monitoring: Blood glucose and HbA1c should be monitored periodically to assess glycemic response. Renal function should be monitored at baseline and during therapy, especially in patients with pre‑existing kidney disease or those experiencing severe gastrointestinal side effects. Serum calcitonin and thyroid ultrasound are not routinely recommended for screening but may be considered if medullary thyroid carcinoma is suspected. Monitor for signs and symptoms of pancreatitis (persistent severe abdominal pain radiating to the back, with or without vomiting) and gallbladder disease (right upper quadrant pain, fever, jaundice).
• Storage: Store unused Ozempic pens in a refrigerator (2 °C to 8 °C). Do not freeze. After first use, the pen may be stored at room temperature (up to 30 °C) or in the refrigerator (2 °C to 8 °C) for up to 6 weeks (42 days). Keep the pen cap on when not in use to protect from light. Do not use Ozempic if it has been frozen. Discard the pen 6 weeks after first use, even if some medication remains. Keep out of the reach and sight of children.
• Lifestyle: Ozempic is most effective when used as part of a comprehensive diabetes or weight‑management plan that includes a healthy diet, regular physical activity, and blood glucose monitoring. Eat smaller, lower‑fat meals to help minimize nausea. Drink plenty of fluids to avoid dehydration from gastrointestinal losses. If you experience persistent nausea or vomiting, contact your doctor, as dose adjustment may be needed.
• Missed dose: If you miss a dose and the next scheduled dose is more than 5 days away, administer the missed dose as soon as possible. If the next dose is due within 5 days, skip the missed dose and take your next dose on the regularly scheduled day. Do not take two doses within 3 days of each other.
• When to seek medical review: Contact your doctor immediately if you experience severe, persistent abdominal pain that may radiate to the back (with or without vomiting), as this may be a sign of acute pancreatitis; right upper abdominal pain, fever, or jaundice, as these may be signs of acute cholecystitis; a new lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath, as these may be signs of a thyroid tumour; or signs of a serious allergic reaction (such as difficulty breathing, swelling of the face, lips, tongue, or throat, hives, or a severe rash).
• Disposal: Dispose of used needles in a sharps disposal container immediately after each injection. Return unused or expired pens to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Other GLP‑1 receptor agonists: Dulaglutide (Trulicity®) is administered once weekly and is available in Canada for type 2 diabetes. In a real‑world head‑to‑head study (REACH), semaglutide was associated with a 23% lower risk of major adverse cardiovascular events compared with dulaglutide. Liraglutide (Victoza®) is a once‑daily GLP‑1 receptor agonist also approved in Canada. Both are reasonable alternatives to Ozempic.
• Tirzepatide (Mounjaro®): A dual glucose‑dependent insulinotropic polypeptide (GIP) and GLP‑1 receptor agonist approved in Canada for type 2 diabetes. It is injected once weekly and may provide greater weight loss and HbA1c reduction than semaglutide.
• Oral semaglutide (Rybelsus®): The oral tablet form of semaglutide, taken once daily on an empty stomach, is available in Canada for patients who prefer not to use an injectable medication.
• SGLT2 inhibitors: Empagliflozin (Jardiance®) and dapagliflozin (Forxiga®) are oral medications that lower blood glucose by blocking glucose reabsorption in the kidneys. They also provide cardiovascular and renal benefits and are first‑line agents for type 2 diabetes.
• Metformin (Glucophage®): The first‑line oral agent for type 2 diabetes, which reduces hepatic glucose production and improves insulin sensitivity. Metformin is often used in combination with Ozempic.
• Wegovy® (semaglutide 2.4 mg): The same active ingredient as Ozempic but at a higher dose and formally approved in Canada for chronic weight management. In practice, Ozempic is often used off‑label for this purpose due to supply and cost considerations.
• Non‑pharmacological approaches: Medical nutrition therapy, regular physical activity, weight loss, blood glucose self‑monitoring, and diabetes self‑management education are foundational components of type 2 diabetes management and are recommended alongside pharmacotherapy. For weight management, cognitive‑behavioural therapy and structured lifestyle‑modification programs are effective adjuncts.

Clinical Efficacy

The clinical efficacy of semaglutide has been evaluated in the global SUSTAIN phase 3 clinical development programme, which included eight randomized, controlled trials involving over 8,000 adults with type 2 diabetes. In the SUSTAIN‑1 trial, Ozempic 0.5 mg and 1 mg once weekly reduced HbA1c by 1.45% and 1.55%, respectively, from a baseline of 8.0%, with 74% and 72% of patients achieving an HbA1c of less than 7.0%, compared with 25% for placebo. In SUSTAIN‑6, the cardiovascular outcomes trial, Ozempic demonstrated a 26% reduction in the composite primary endpoint of cardiovascular death, non‑fatal myocardial infarction, and non‑fatal stroke (hazard ratio [HR] 0.74; 95% CI 0.58‑0.95) compared with placebo over a median follow‑up of 2.1 years. The SOUL trial, a dedicated cardiovascular outcomes study with oral semaglutide in adults with type 2 diabetes at high risk for atherosclerotic cardiovascular disease, showed a 14% reduction in major adverse cardiovascular events.

The REACH real‑world study compared Ozempic with dulaglutide in over 86,000 older adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Ozempic was associated with a 23% lower risk of the composite of myocardial infarction, stroke, or death compared with dulaglutide. In the SELECT trial, semaglutide 2.4 mg (Wegovy) reduced the risk of major adverse cardiovascular events by 20% compared with placebo in adults with overweight or obesity and pre‑existing cardiovascular disease but without diabetes.

In Canada, the CADTH Canadian Drug Expert Committee (CDEC) has recommended that Ozempic be reimbursed for the treatment of adults with type 2 diabetes mellitus, with clinical criteria. The 2025 Diabetes Canada clinical practice guidelines recommend GLP‑1 receptor agonists, including semaglutide, as second‑line agents after metformin for patients with type 2 diabetes who have not achieved glycemic targets, particularly in patients with established cardiovascular disease, chronic kidney disease, or in whom weight loss is a treatment goal. The consistent and robust cardiovascular benefits, combined with meaningful reductions in HbA1c and body weight, have established semaglutide as a leading therapy in the modern management of type 2 diabetes and, in the appropriate formulation, as a breakthrough agent for chronic weight management.

Important:

Ozempic (semaglutide) is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It carries a boxed warning for the risk of thyroid C‑cell tumours, including medullary thyroid carcinoma (MTC). Ozempic is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Inform your doctor immediately if you develop a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. Acute pancreatitis, including fatal cases, has been reported. Discontinue Ozempic immediately and seek medical attention if you experience severe abdominal pain that may radiate to the back, with or without vomiting. Severe gastrointestinal adverse events, including stomach paralysis (gastroparesis) and intestinal obstruction, have been reported. Do not share your Ozempic pen with others, even if the needle has been changed. Ozempic should not be used during pregnancy or breastfeeding. If you are planning a pregnancy, Ozempic should be discontinued at least 2 months in advance. Use a new needle for each injection and dispose of it safely. Store your pen according to the manufacturer’s directions and discard it 6 weeks after first use. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Ozempic Injection - Shipping across Canada